UBS reiterates its Buy recommendation on the stock, with a target price of E110, which represents a potential upside of 19%.

'Guidance for fiscal 2024 has already been defined. Higher taxes and R&D will lead to lower EPS, but UBS expects strong growth from 2025 onwards as growth diversifies away from Dupixent' says UBS.

According to the healthcare group, newly launched or soon-to-be-launched pharmaceutical assets should generate more than €10 billion in annual sales by 2030, to which will be added solid growth from Dupixent and vaccines.

' Sanofi has raised its expectations for Dupixent and the assets that could replace Dupixent sales in the future,' said UBS.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.